$GANX
Gain Therapeutics, Inc.

2024 Q1 Form 10-K Financial Statement

#000155837024003943 Filed on March 26, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $55.18K
YoY Change -100.0% -60.62%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.907M $2.033M $10.88M
YoY Change -23.55% -11.11% 14.09%
% of Gross Profit
Research & Development $2.507M $2.374M $11.38M
YoY Change -10.19% 4.4% 35.83%
% of Gross Profit
Depreciation & Amortization $20.53K $23.59K $83.58K
YoY Change 6.68% 30.26% 30.25%
% of Gross Profit
Operating Expenses $4.378M $4.407M $22.31M
YoY Change -17.17% -3.38% 24.51%
Operating Profit -$4.378M -$22.25M
YoY Change -16.29% 25.18%
Interest Expense $383.4K -$302.2K $64.88K
YoY Change 251.08% 759.61% -76.77%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$3.994M -$4.709M -$22.19M
YoY Change -21.99% 2.46% 26.81%
Income Tax $19.87K $14.50K $79.28K
% Of Pretax Income
Net Earnings -$4.014M -$4.724M -$22.27M
YoY Change -21.86% 1.06% 26.59%
Net Earnings / Revenue -40354.33%
Basic Earnings Per Share -$0.22 -$1.71
Diluted Earnings Per Share -$0.22 -$0.31 -$1.71
COMMON SHARES
Basic Shares Outstanding 16.22M 12.91M 13.01M
Diluted Shares Outstanding 17.98M 13.01M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.66M $16.79M $16.79M
YoY Change -28.94% -16.6% -16.6%
Cash & Equivalents $10.64M $6.767M $6.767M
Short-Term Investments $2.019M $5.000M $5.000M
Other Short-Term Assets $952.9K $741.6K $741.6K
YoY Change -28.66% -2.6% -2.6%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.86M $17.78M $17.78M
YoY Change -28.26% -15.71% -15.71%
LONG-TERM ASSETS
Property, Plant & Equipment $111.9K $778.6K $778.6K
YoY Change -22.63% 439.24% -23.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change -100.0% -100.0%
Other Assets $49.36K $51.91K $51.91K
YoY Change 1.19% 7.43% 7.43%
Total Long-Term Assets $714.7K $830.5K $830.5K
YoY Change -64.28% -72.39% -72.39%
TOTAL ASSETS
Total Short-Term Assets $13.86M $17.78M $17.78M
Total Long-Term Assets $714.7K $830.5K $830.5K
Total Assets $14.58M $18.61M $18.61M
YoY Change -31.63% -22.78% -22.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.400M $1.319M $1.319M
YoY Change -36.36% -18.89% -18.89%
Accrued Expenses $1.102M $1.973M $1.973M
YoY Change -12.74% 82.31% 0.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $110.8K $118.8K $118.8K
YoY Change 1.51% 9.86% 9.86%
Total Short-Term Liabilities $5.004M $4.950M $4.950M
YoY Change -2.93% 19.99% 19.99%
LONG-TERM LIABILITIES
Long-Term Debt $396.8K $449.1K $449.1K
YoY Change -17.03% -9.33% -9.33%
Other Long-Term Liabilities $534.2K $632.1K $632.1K
YoY Change -2.97% 5.46% 5.46%
Total Long-Term Liabilities $931.0K $1.081M $1.081M
YoY Change -9.51% -1.23% -1.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.004M $4.950M $4.950M
Total Long-Term Liabilities $931.0K $1.081M $1.081M
Total Liabilities $5.935M $6.031M $6.031M
YoY Change -4.02% 15.54% 15.54%
SHAREHOLDERS EQUITY
Retained Earnings -$60.78M -$38.52M
YoY Change 57.81% 84.06%
Common Stock $1.805K $1.621K
YoY Change 49.3% 36.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.642M $12.58M $12.58M
YoY Change
Total Liabilities & Shareholders Equity $14.58M $18.61M $18.61M
YoY Change -31.63% -22.78% -22.78%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$4.014M -$4.724M -$22.27M
YoY Change -21.86% 1.06% 26.59%
Depreciation, Depletion And Amortization $20.53K $23.59K $83.58K
YoY Change 6.68% 30.26% 30.25%
Cash From Operating Activities -$3.587M -$5.660M -$18.87M
YoY Change -14.96% 44.97% 28.41%
INVESTING ACTIVITIES
Capital Expenditures $20.00 $15.36K
YoY Change -99.79% -87.09%
Acquisitions
YoY Change
Other Investing Activities $3.019M $3.142M $10.24M
YoY Change 42.53% 2093.59% -169.86%
Cash From Investing Activities $3.019M $3.142M $10.22M
YoY Change 43.27% 2247.65% -169.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $12.73M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -145.8K 9.561M 12.64M
YoY Change -119.47% -44403.01% -16147.6%
NET CHANGE
Cash From Operating Activities -3.587M -5.660M -18.87M
Cash From Investing Activities 3.019M 3.142M 10.22M
Cash From Financing Activities -145.8K 9.561M 12.64M
Net Change In Cash -1.156M 7.042M 3.998M
YoY Change -12.62% -285.69% -113.52%
FREE CASH FLOW
Cash From Operating Activities -$3.587M -$5.660M -$18.87M
Capital Expenditures $20.00 $15.36K
Free Cash Flow -$5.660M -$18.88M
YoY Change 44.62% 27.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023 us-gaap Defined Benefit Plan Net Periodic Benefit Cost Credit Interest Cost Statement Of Income Or Comprehensive Income Extensible List
DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2023#InterestIncomeExpenseNet
CY2023 us-gaap Defined Benefit Plan Net Periodic Benefit Cost Credit Expected Return Loss Statement Of Income Or Comprehensive Income Extensible List
DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2023#InterestIncomeExpenseNet
CY2023 us-gaap Defined Benefit Plan Net Periodic Benefit Cost Credit Amortization Of Gain Loss Statement Of Income Or Comprehensive Income Extensible List
DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2023#InterestIncomeExpenseNet
CY2023 us-gaap Defined Benefit Plan Net Periodic Benefit Cost Credit Amortization Of Prior Service Cost Credit Statement Of Income Or Comprehensive Income Extensible List
DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfPriorServiceCostCreditStatementOfIncomeOrComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2023#InterestIncomeExpenseNet
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001819411
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16206680
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11883368
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16206680
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11883368
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-40237
CY2023 dei Entity Registrant Name
EntityRegistrantName
GAIN THERAPEUTICS, INC
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1726310
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
4800 Montgomery Lane
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 220
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Bethesda
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20814
CY2023 dei City Area Code
CityAreaCode
301
CY2023 dei Local Phone Number
LocalPhoneNumber
500-1556
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
1122138
CY2022Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
55180
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
118797
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
108135
CY2023 dei Trading Symbol
TradingSymbol
GANX
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
56600000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16219709
CY2023 dei Auditor Firm
AuditorFirmId
1460
CY2023 dei Auditor Name
AuditorName
Ernst & Young AG
CY2023 dei Auditor Location
AuditorLocation
Lugano, Switzerland
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11794949
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7311611
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
4999704
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
12826954
CY2023Q4 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
242577
CY2022Q4 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
103877
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
741638
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
848854
CY2023Q4 us-gaap Assets Current
AssetsCurrent
17778868
CY2022Q4 us-gaap Assets Current
AssetsCurrent
21091296
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1941488
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
125962
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
144379
CY2023Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
193375
CY2022Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
213967
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
459215
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
659933
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
34021
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
30818
CY2023Q4 ganx Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
17890
CY2022Q4 ganx Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
17506
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
830463
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
3008091
CY2023Q4 us-gaap Assets
Assets
18609331
CY2022Q4 us-gaap Assets
Assets
24099387
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1318965
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1626100
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
229693
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
229080
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2160366
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2106756
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4949959
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4125251
CY2023Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
307454
CY2022Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
157580
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
229855
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
441784
CY2023Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
94786
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
449053
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
495258
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1081148
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1094622
CY2023Q4 us-gaap Liabilities
Liabilities
6031107
CY2022Q4 us-gaap Liabilities
Liabilities
5219873
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16206680
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11883368
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1621
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1189
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
73113079
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
57358895
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
247241
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
35627
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38516197
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20925459
CY2023Q4 ganx Income Loss For Period
IncomeLossForPeriod
-22267520
CY2022Q4 ganx Income Loss For Period
IncomeLossForPeriod
-17590738
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12578224
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
18879514
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18609331
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24099387
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55180
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
132640
CY2022 us-gaap Sublease Income
SubleaseIncome
7468
CY2023 us-gaap Revenues
Revenues
55180
CY2022 us-gaap Revenues
Revenues
140108
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11520613
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8377290
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10787700
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9539863
CY2023 us-gaap Operating Expenses
OperatingExpenses
22308313
CY2022 us-gaap Operating Expenses
OperatingExpenses
17917153
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-22253133
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-17777045
CY2023 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
494234
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
375357
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-429346
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-96074
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22188245
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17497762
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
79275
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
92976
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-22267520
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-17590738
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.71
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.71
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.48
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.48
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13011361
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13011361
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11883368
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11883368
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-22267520
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-17590738
CY2023 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
89304
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-94279
CY2023 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
127601
CY2022 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-227131
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
249911
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6580
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
211614
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
126272
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22055906
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17464466
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
18879514
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3305072
CY2023 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
127601
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
249911
CY2023 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
89304
CY2023 ganx Stock Issued During Period Value At Market Offering
StockIssuedDuringPeriodValueAtMarketOffering
3544876
CY2023 ganx Stock Issued During Period Value New Issues Public Offering And Private Placement
StockIssuedDuringPeriodValueNewIssuesPublicOfferingAndPrivatePlacement
8904668
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-22267520
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12578224
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
34817546
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1526434
CY2022 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-227131
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6580
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-94279
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-17590738
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
18879514
CY2023 us-gaap Profit Loss
ProfitLoss
-22267520
CY2022 us-gaap Profit Loss
ProfitLoss
-17590738
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
83579
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
64168
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
3259026
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1526434
CY2023 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
383188
CY2022 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
206861
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-184446
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
114005
CY2023 ganx Increase Decrease In Value Added Tax Credits
IncreaseDecreaseInValueAddedTaxCredits
130068
CY2022 ganx Increase Decrease In Value Added Tax Credits
IncreaseDecreaseInValueAddedTaxCredits
-3631
CY2023 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
10057
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2901
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-643164
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1066707
CY2023 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-50534
CY2022 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
711073
CY2023 ganx Non Cash Increase Decrease In Defined Benefit Pension Plan Obligation Asset
NonCashIncreaseDecreaseInDefinedBenefitPensionPlanObligationAsset
6313
CY2022 ganx Non Cash Increase Decrease In Defined Benefit Pension Plan Obligation Asset
NonCashIncreaseDecreaseInDefinedBenefitPensionPlanObligationAsset
58696
CY2023 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
1085294
CY2022 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-208343
CY2023 us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
-442230
CY2022 us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
-1514858
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18865873
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14692139
CY2023 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
15358
CY2022 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
118953
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1956350
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
17735355
CY2023 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
12194375
CY2022 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
3079495
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10222667
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14774813
CY2023 ganx Proceeds From Issuance Of Common Stock In At Market Offerings
ProceedsFromIssuanceOfCommonStockInAtMarketOfferings
3544876
CY2023 ganx Proceeds From Issuance Of Shares And Warrants In Public Offering And Private Placement
ProceedsFromIssuanceOfSharesAndWarrantsInPublicOfferingAndPrivatePlacement
9185534
CY2023 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
89067
CY2022 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
78774
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12641343
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-78774
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
488404
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-23797
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4486541
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29569523
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7342429
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36911952
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11828970
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7342429
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
134962
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2740
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
10
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
16800000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
408487
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
158576
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of our consolidated financial statements in conformity with US GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates judgments and, assumptions including those related to the assessment of going concern, recognition of accrued expenses, defined benefit pension liability, share-based compensation, recognition of research grants. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. Changes in estimates are recorded in the period in which they become known. To the extent that material differences arise between the estimates and actual results, the Company’s future results of operations will be affected. </p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Concentrations of credit risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has no significant off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that may expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents which are deposited in accredited financial institutions in excess of federally insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p>
CY2023Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
193375
CY2022Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
213967
CY2023 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
45507
CY2022 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
37536
CY2023Q4 us-gaap Capitalized Computer Software Accumulated Amortization
CapitalizedComputerSoftwareAccumulatedAmortization
91262
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0153
CY2022Q4 us-gaap Capitalized Computer Software Accumulated Amortization
CapitalizedComputerSoftwareAccumulatedAmortization
39021
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11794949
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7311611
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
34021
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
30818
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
5004679
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4975
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
4999704
CY2023Q4 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
242577
CY2022Q4 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
103877
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
608638
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
552882
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
87430
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
133000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
208542
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
741638
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
848854
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
218759
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
197708
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
92797
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
53329
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
125962
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
144379
CY2022 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2023 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2023 us-gaap Depreciation
Depreciation
34875
CY2022 us-gaap Depreciation
Depreciation
26632
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
459215
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
659933
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
229693
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
229080
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
229855
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
441784
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y18D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0151
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
246165
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
228739
CY2023Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
234576
CY2023Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
174585
CY2023Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
57889
CY2023Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
467050
CY2023Q4 ganx Adjustment To Reconcile Operating Lease Liabilities Amounts Representing Interest Or Imputed Interest
AdjustmentToReconcileOperatingLeaseLiabilitiesAmountsRepresentingInterestOrImputedInterest
7502
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
459548
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1300000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1600000
CY2023Q4 ganx Payable For Social Securities Current
PayableForSocialSecuritiesCurrent
368345
CY2022Q4 ganx Payable For Social Securities Current
PayableForSocialSecuritiesCurrent
256798
CY2023Q4 ganx Accrued Payroll Current
AccruedPayrollCurrent
726474
CY2022Q4 ganx Accrued Payroll Current
AccruedPayrollCurrent
660556
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1016582
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1082091
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
48965
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
107311
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2160366
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.52
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2106756
CY2023Q4 us-gaap Deferred Income
DeferredIncome
1216924
CY2022Q4 us-gaap Deferred Income
DeferredIncome
55180
CY2023Q4 us-gaap Deferred Credits And Other Liabilities Current
DeferredCreditsAndOtherLiabilitiesCurrent
3377290
CY2022Q4 us-gaap Deferred Credits And Other Liabilities Current
DeferredCreditsAndOtherLiabilitiesCurrent
2161936
CY2023 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
19938
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
15875
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
567850
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
118797
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
95038
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
95038
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
95038
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
95038
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
68901
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16206680
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11883368
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
10100000
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1200000
CY2023Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
900000
CY2023Q4 ganx Warrants And Rights Exercised Or Exchanged Number
WarrantsAndRightsExercisedOrExchangedNumber
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1879662
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.42
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.94
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M6D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
721850
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.81
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.40
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
27213
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.03
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
3.66
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2574299
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
15977
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
20011
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
15977
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
20011
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.06
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1516053
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.33
CY2023Q4 ganx Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Fair Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare
2.77
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y11M4D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1516053
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.33
CY2023Q4 ganx Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageFairValue
2.77
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y11M4D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.40
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.49
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.77
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y7M6D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y2M26D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0349
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0339
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3259026
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1526434
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3480000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-22477695
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-17341701
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
289450
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-156061
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22188245
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17497762
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
79275
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
92976
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
79275
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
92976
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
79275
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
92976
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
38783199
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
34289160
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
7662929
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
6283703
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
2001169
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
2140174
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
820078
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
399538
CY2023Q4 ganx Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost Foreign
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCostForeign
96173
CY2022Q4 ganx Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost Foreign
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCostForeign
41093
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
947754
CY2023Q4 ganx Deferred Tax Assets Warrant Expense
DeferredTaxAssetsWarrantExpense
278198
CY2022Q4 ganx Deferred Tax Assets Warrant Expense
DeferredTaxAssetsWarrantExpense
278198
CY2023Q4 ganx Deferred Tax Assets Patent Expenses
DeferredTaxAssetsPatentExpenses
103386
CY2022Q4 ganx Deferred Tax Assets Patent Expenses
DeferredTaxAssetsPatentExpenses
202149
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
147245
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
117371
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
12056932
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
9462226
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12040955
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9442215
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0241
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0622
CY2023 ganx Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0948
CY2022 ganx Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0017
CY2023 ganx Effective Income Tax Rate Reconciliation Provision To Return
EffectiveIncomeTaxRateReconciliationProvisionToReturn
-0.0280
CY2022 ganx Effective Income Tax Rate Reconciliation Provision To Return
EffectiveIncomeTaxRateReconciliationProvisionToReturn
-0.0013
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.0004
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0012
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1153
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2733
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0036
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0053
CY2022Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2022 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2023 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-003943-index-headers.html Edgar Link pending
0001558370-24-003943-index.html Edgar Link pending
0001558370-24-003943.txt Edgar Link pending
0001558370-24-003943-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ganx-20231231.xsd Edgar Link pending
ganx-20231231x10k.htm Edgar Link pending
ganx-20231231x10k001.jpg Edgar Link pending
ganx-20231231x10k002.jpg Edgar Link pending
ganx-20231231x10k003.jpg Edgar Link pending
ganx-20231231x10k004.jpg Edgar Link pending
ganx-20231231x10k005.jpg Edgar Link pending
ganx-20231231x10k006.jpg Edgar Link pending
ganx-20231231x10k007.jpg Edgar Link pending
ganx-20231231xex23d1.htm Edgar Link pending
ganx-20231231xex31d1.htm Edgar Link pending
ganx-20231231xex31d2.htm Edgar Link pending
ganx-20231231xex32d1.htm Edgar Link pending
ganx-20231231xex4d1.htm Edgar Link pending
ganx-20231231xex97d1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ganx-20231231_cal.xml Edgar Link unprocessable
ganx-20231231x10k_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ganx-20231231_def.xml Edgar Link unprocessable
ganx-20231231_pre.xml Edgar Link unprocessable
ganx-20231231_lab.xml Edgar Link unprocessable